Novel 1,5-benzodiazepines as CCK-B ligands. Effect of aryl-carbamic substituents at the C-3 position together with halogen substitution on the benzo-fused ring.
Tranquillini
M E
ME
Glaxo Wellcome S.p.A., Medicines Research Centre, Verona, Italy.
Cassarà
P G
PG
Corsi
M
M
Curotto
G
G
Donati
D
D
Finizia
G
G
Pentassuglia
G
G
Polinelli
S
S
Tarzia
G
G
Ursini
A
A
van Amsterdam
F T
FT
D000818:Animals; D001569:Benzodiazepines / Q000138:chemical synthesis* / Q000378:metabolism* / Q000494:pharmacology; D006168:Guinea Pigs; D006846:Hydrocarbons, Halogenated / Q000138:chemical synthesis* / Q000378:metabolism* / Q000494:pharmacology; D007700:Kinetics; D008024:Ligands; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin / Q000378:metabolism*; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D006846:Hydrocarbons, Halogenated; D008024:Ligands; D043887:Receptor, Cholecystokinin B; D011949:Receptors, Cholecystokinin; D001569:Benzodiazepines